|
Re: Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
|
4
|
Zenith Epigenetics
|
Jun 27, 2019 10:43AM
|
|
Re: Reaching 250 MACE
|
4
|
Resverlogix Corp.
|
Apr 23, 2019 11:10AM
|
|
Re: Early Warning Report
|
4
|
Zenith Epigenetics
|
Nov 29, 2020 09:55AM
|
|
Re: We broke through the Resistance at $2.15
|
4
|
Resverlogix Corp.
|
Oct 05, 2016 02:53PM
|
|
Re: One week til the EAS Congress in Prague....April 2017 Fact Sheet PDF
|
4
|
Resverlogix Corp.
|
Apr 15, 2017 01:03PM
|
|
Re: Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease
|
4
|
Resverlogix Corp.
|
Apr 27, 2021 04:02PM
|
|
Re: BIO-Europe Presentation
|
4
|
Resverlogix Corp.
|
Mar 15, 2018 08:20AM
|
|
Re: Slide 27 - I would get rid of it....
|
4
|
Resverlogix Corp.
|
Sep 17, 2016 05:17PM
|
|
Re: Zenith Epigenetics did not respond to invitatations in this one
|
4
|
Zenith Epigenetics
|
May 31, 2021 01:14PM
|
|
Re: At least we're getting some intersting trading...
|
4
|
Resverlogix Corp.
|
Mar 09, 2017 10:03AM
|
|
Re: Shrinking MACE event rate
|
4
|
Resverlogix Corp.
|
Jan 20, 2019 09:19AM
|
|
Re: RVV insider purchases
|
5
|
Resverlogix Corp.
|
Dec 16, 2022 10:28AM
|
|
Re: News from a Chinese/Japenese Article about Zenith
|
5
|
Zenith Epigenetics
|
Oct 26, 2016 07:31PM
|
|
Re: Trillium
|
5
|
Zenith Epigenetics
|
Aug 26, 2021 11:25AM
|
|
Re: New RVX Publication in Atherosclerosis
|
5
|
Resverlogix Corp.
|
Jan 24, 2016 02:43PM
|
|
Re: Market:FDA Not Enough ??
|
5
|
Resverlogix Corp.
|
Jul 25, 2017 10:48AM
|
|
Re: A comment by BDZ on SH...
|
5
|
Resverlogix Corp.
|
Apr 27, 2017 12:24PM
|
|
Re: Resverlogix and Zenith AGMs
|
5
|
Resverlogix Corp.
|
Aug 23, 2016 11:40AM
|
|
Re: Age, MoCA and CKD
|
5
|
Resverlogix Corp.
|
Nov 19, 2019 02:59PM
|
|
Re: Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference
|
5
|
Zenith Epigenetics
|
Jun 21, 2022 09:16AM
|
